Latest News & Updates

Breaking News

  • 1 day ago

  • Vaibhavi M.

Roche Gains FDA Priority Review for Colon Cancer Drug with October 2026 Decision Date
Breaking News
AbbVie Acquires Apogee Biologics in $10.9 Billion Deal to Extend Immunology Pipeline

Vaibhavi M.

Other trending news you may like to read

Roche Gains FDA Priority Review for Colon Cancer Drug with October 2026 Decision Date

FDA grants Roche Priority Review for a colon cancer drug, setting a 9 October 2026 decision date after trial data showed 50% recurrence reduction.

Vaibhavi M.

Pharma Now

AbbVie Acquires Apogee Biologics in $10.9 Billion Deal to Extend Immunology Pipeline

AbbVie acquires Apogee for $10.9B, raising immediate tech transfer and GMP integration questions for biologics manufacturing teams.

Vaibhavi M.

Pharma Now

Wesley Pharmaceuticals Launches Three Injectable Formulations Expanding Its 503(b) Outsourcing Portfolio

Wesley Pharmaceuticals launches three 503(b)-compliant multi-dose injectables, expanding outsourcing supply options for health networks.

Vaibhavi M.

Pharma Now

Allergan Aesthetics Gains Health Canada Approval for Boey® as First Botulinum Serotype E Neurotoxin

Health Canada approves Boey® (trenibotulinumtoxinE), the world's first botulinum serotype E aesthetic neurotoxin, setting a new biologics regulatory precedent.

Vaibhavi M.

Pharma Now